AAAAAA

ITA
ENG

Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Clinical immunotherapeutics

Results: 1-25/272

UNTITLED

Authors: BEEDLE AS

Citation: As. Beedle, UNTITLED, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 421-423

ALLERGIC REACTIONS TO FOOD - IS THERE A BASIS FOR PHARMACOLOGICAL TREATMENT

Authors: OEHLING AK

Citation: Ak. Oehling, ALLERGIC REACTIONS TO FOOD - IS THERE A BASIS FOR PHARMACOLOGICAL TREATMENT, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 424-430

IMMUNOSUPPRESSANT THERAPY FOR IDIOPATHIC PULMONARY FIBROSIS

Authors: BAUGHMAN RP LOWER EE

Citation: Rp. Baughman et Ee. Lower, IMMUNOSUPPRESSANT THERAPY FOR IDIOPATHIC PULMONARY FIBROSIS, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 431-442

NOCTURNAL ASTHMA - THERAPEUTIC CONSIDERATIONS

Authors: MARTIN RJ KRAFT M

Citation: Rj. Martin et M. Kraft, NOCTURNAL ASTHMA - THERAPEUTIC CONSIDERATIONS, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 443-453

IMMUNOMODULATORY ACTIONS OF ANTIBACTERIAL AGENTS

Authors: LABRO MT

Citation: Mt. Labro, IMMUNOMODULATORY ACTIONS OF ANTIBACTERIAL AGENTS, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 454-464

COMBINATION OF VITAMIN-D ANALOGS AND IMMUNOSUPPRESSANTS - POTENTIAL CLINICAL USE

Authors: BRANISTEANU DD MATHIEU C CASTEELS K BOUILLON R

Citation: Dd. Branisteanu et al., COMBINATION OF VITAMIN-D ANALOGS AND IMMUNOSUPPRESSANTS - POTENTIAL CLINICAL USE, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 465-478

IMMUNOSUPPRESSIVE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - CURRENT STATUS AND RECOMMENDATIONS

Authors: DEMARIA N COLANTONI A VANTHIEL DH

Citation: N. Demaria et al., IMMUNOSUPPRESSIVE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - CURRENT STATUS AND RECOMMENDATIONS, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 479-488

COMBINATION OF INHALED CORTICOSTEROIDS AND BETA(2)-AGONISTS IN ASTHMA- CLINICAL AND ECONOMIC-IMPLICATIONS

Authors: RUTTENVANMOLKEN MPMH KERSTJENS HAM

Citation: Mpmh. Ruttenvanmolken et Ham. Kerstjens, COMBINATION OF INHALED CORTICOSTEROIDS AND BETA(2)-AGONISTS IN ASTHMA- CLINICAL AND ECONOMIC-IMPLICATIONS, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 489-505

PIRAZOLAC

Authors: LEA AP GOA KL

Citation: Ap. Lea et Kl. Goa, PIRAZOLAC, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 506-510

PIRAZOLAC - A VIEWPOINT

Authors: EMERY P

Citation: P. Emery, PIRAZOLAC - A VIEWPOINT, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 511-511

PIRAZOLAC - A VIEWPOINT

Authors: LAURENT R

Citation: R. Laurent, PIRAZOLAC - A VIEWPOINT, CLINICAL IMMUNOTHERAPEUTICS, 6(6), 1996, pp. 511-511

EICOSANOIDS IN INFLAMMATORY BOWEL-DISEASE - THERAPEUTIC IMPLICATIONS

Authors: CASELLAS F GUARNER F

Citation: F. Casellas et F. Guarner, EICOSANOIDS IN INFLAMMATORY BOWEL-DISEASE - THERAPEUTIC IMPLICATIONS, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 333-340

CHRONIC URTICARIA - PRACTICAL RECOMMENDATIONS FOR MANAGEMENT

Authors: ODONNELL BF LAWLOR F

Citation: Bf. Odonnell et F. Lawlor, CHRONIC URTICARIA - PRACTICAL RECOMMENDATIONS FOR MANAGEMENT, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 341-351

MANAGEMENT OF VIRAL-INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS

Authors: DIX SP WINGARD JR

Citation: Sp. Dix et Jr. Wingard, MANAGEMENT OF VIRAL-INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 352-382

POTENTIAL USE OF INTERFERON-ALPHA IN OPHTHALMOLOGICAL DISORDERS

Authors: GILLIES MC

Citation: Mc. Gillies, POTENTIAL USE OF INTERFERON-ALPHA IN OPHTHALMOLOGICAL DISORDERS, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 383-394

CYTOKINE-SUPPRESSIVE ANTIINFLAMMATORY DRUGS - STATUS OF DEVELOPMENT IN RHEUMATOID-ARTHRITIS

Authors: HUIZINGA TWJ BREEDVELD FC

Citation: Twj. Huizinga et Fc. Breedveld, CYTOKINE-SUPPRESSIVE ANTIINFLAMMATORY DRUGS - STATUS OF DEVELOPMENT IN RHEUMATOID-ARTHRITIS, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 395-404

HIGH DOSAGE CORTICOSTEROIDS IN THE TREATMENT OF OPTIC NEURITIS AND PROPHYLAXIS OF MULTIPLE-SCLEROSIS

Authors: GOODWIN J

Citation: J. Goodwin, HIGH DOSAGE CORTICOSTEROIDS IN THE TREATMENT OF OPTIC NEURITIS AND PROPHYLAXIS OF MULTIPLE-SCLEROSIS, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 405-412

EDOBACOMAB

Authors: HARIA M MCTAVISH D

Citation: M. Haria et D. Mctavish, EDOBACOMAB, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 413-419

EDOBACOMAB - A VIEWPOINT

Authors: BONE RC

Citation: Rc. Bone, EDOBACOMAB - A VIEWPOINT, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 420-420

EDOBACOMAB - A VIEWPOINT

Authors: LYNN WA

Citation: Wa. Lynn, EDOBACOMAB - A VIEWPOINT, CLINICAL IMMUNOTHERAPEUTICS, 6(5), 1996, pp. 420-420

INTERLEUKIN-4 - POTENTIAL IMMUNOREGULATORY AGENT IN THERAPY OF INSULIN-DEPENDENT DIABETES-MELLITUS

Authors: ARREAZA GA CAMERON MJ DELOVITCH TL

Citation: Ga. Arreaza et al., INTERLEUKIN-4 - POTENTIAL IMMUNOREGULATORY AGENT IN THERAPY OF INSULIN-DEPENDENT DIABETES-MELLITUS, CLINICAL IMMUNOTHERAPEUTICS, 6(4), 1996, pp. 251-260

HEPATITIS-A PROPHYLAXIS - VACCINE OR IMMUNOGLOBULIN

Authors: ADLER R SHOUVAL D

Citation: R. Adler et D. Shouval, HEPATITIS-A PROPHYLAXIS - VACCINE OR IMMUNOGLOBULIN, CLINICAL IMMUNOTHERAPEUTICS, 6(4), 1996, pp. 261-272

DELIVERY DEVICES FOR INHALED ASTHMA MEDICATION - CLINICAL IMPLICATIONS OF DIFFERENCES IN EFFECTIVENESS

Authors: SELROOS O PIETINALHO A RISKA H

Citation: O. Selroos et al., DELIVERY DEVICES FOR INHALED ASTHMA MEDICATION - CLINICAL IMPLICATIONS OF DIFFERENCES IN EFFECTIVENESS, CLINICAL IMMUNOTHERAPEUTICS, 6(4), 1996, pp. 273-299

LEFLUNOMIDE

Authors: PLOSKER GL WAGSTAFF AJ

Citation: Gl. Plosker et Aj. Wagstaff, LEFLUNOMIDE, CLINICAL IMMUNOTHERAPEUTICS, 6(4), 1996, pp. 300-305

LEFLUNOMIDE - A VIEWPOINT

Authors: EMERY P

Citation: P. Emery, LEFLUNOMIDE - A VIEWPOINT, CLINICAL IMMUNOTHERAPEUTICS, 6(4), 1996, pp. 306-306

Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>